2R,4S,5S-6-cyclohexyl-5-(t-butoxycarbonylamino)-2-(2'-methyl-2'-propenyl)-gamma-hexanolactone | 112228-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 2R,4S,5S-6-cyclohexyl-5-(t-butoxycarbonylamino)-2-(2'-methyl-2'-propenyl)-gamma-hexanolactone
• 英文别名: tert-butyl N-[(1S)-2-cyclohexyl-1-[(2S,4R)-4-(2-methylprop-2-enyl)-5-oxooxolan-2-yl]ethyl]carbamate
• CAS: 112228-21-4
• 化学式: C₂₁H₃₅NO₄
• 分子量: 365.513
• InChiKey: MTWNQBZEOCMXBE-SQNIBIBYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2R,4S,5S-6-cyclohexyl-5-(t-butoxycarbonylamino)-2-(2'-methyl-2'-propenyl)-gamma-hexanolactone 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 2R,4S,5S-6-Cyclohexyl-5-(t-butoxycarbonylamino)-2-(2-methylpropyl)-gamma-hexanolactone
  参考文献：
  名称：

  The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template

  摘要：

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.020
• 作为产物：
  描述：

  3-溴-2-甲基丙烯 、 (5S)-5-[(1S)-1-(N-t-butoxycarbonylamino)-2-cyclohexylethyl]dihydrofuran-2(3H)-one 在 lithium hexamethyldisilazane 作用下， 反应 3.0h， 以54%的产率得到2R,4S,5S-6-cyclohexyl-5-(t-butoxycarbonylamino)-2-(2'-methyl-2'-propenyl)-gamma-hexanolactone
  参考文献：
  名称：

  The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template

  摘要：

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.020

文献信息

• Certain heterocyclic-hexanamides useful for treating hypertension
  申请人：Pfizer Inc.

  公开号：US04923864A1

  公开（公告）日：1990-05-08

  Simple amides and derivatives thereof useful for inhibiting the angiotensinogen-cleaving action of the enzyme renin.

  简单酰胺及其衍生物可用于抑制酶肾素的切割作用。
• KLEINMAN, EDWARD F.;ROSATI, ROBERT L.;BINDRA, JASJIT S.
  作者：KLEINMAN, EDWARD F.、ROSATI, ROBERT L.、BINDRA, JASJIT S.

  DOI：——

  日期：——
• US4923864A
  申请人：——

  公开号：US4923864A

  公开（公告）日：1990-05-08
• The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template
  作者：John C Kath、Amy P DiRico、Ronald P Gladue、William H Martin、Eric B McElroy、Ingrid A Stock、Laurie A Tylaska、Deye Zheng

  DOI：10.1016/j.bmcl.2004.02.020

  日期：2004.5

  The present manuscript details the discovery and early fundamental structure-activity relationship studies, involving compound 3, a novel hydroxyethylene peptide isostere derived molecule that provides micromolar inhibition of CCL3 binding to its receptor CCR1. Initial studies established this screening hit as a legitimate lead for further medicinal chemistry optimization. (C) 2004 Elsevier Ltd. All rights reserved.